Chong Kun Dang Holdings Corp.

A001630

KR7001630003

Food Processing

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
60,700 ^KRW	+0.66%		+0.50%	+2.53%

Feb. 06	Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on August 12, 2022.	CI
Feb. 06	Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on August 12, 2022.	CI

Chong Kun Dang Holdings Corp. announces an Equity Buyback for KRW 5,000 million worth of its shares.

October 14, 2021

Chong Kun Dang Holdings Corp. (KOSE:A001630) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a contract with NH Investment & Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price.

The program will expire on October 14, 2022. As of October 14, 2021, the company had 51,309 shares in treasury within the scope available for dividend and 24 shares in treasury through other repurchases.

Latest news about Chong Kun Dang Holdings Corp.

Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on August 12, 2022.	Feb. 06	CI
Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on August 12, 2022.	Feb. 06	CI
Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on August 12, 2022.	Feb. 06	CI
Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on August 12, 2022.	Feb. 06	CI
Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on August 12, 2022.	Feb. 06	CI
Chong Kun Dang Holdings Corp.'s Equity Buyback announced on August 12, 2022, has expired with 122,110 shares, representing 2.52% for KRW 6,366.04 million.	Feb. 04	CI
Chong Kun Dang Pharmaceutical Inks Largest-Ever Technology Transfer Agreement with Novartis	Nov. 08	MT
Chong Kun Dang Holdings Corp.(KOSE:A001630) dropped from S&P Global BMI Index	23-09-18	CI
Chong Kun Dang Holdings Corp.'s Equity Buyback Plan Extended till August 11, 2024.	23-08-10	CI
Chong Kun Dang Holdings Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Chong Kun Dang Holdings Corp.'s Equity Buyback announced on February 10, 2022, has expired.	23-02-08	CI
Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on August 12, 2022.	22-11-15	CI
Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on October 15, 2021.	22-10-18	CI
Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on October 15, 2021.	22-10-18	CI
Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on October 15, 2021.	22-10-18	CI
Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on October 15, 2021.	22-10-18	CI
Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on October 15, 2021.	22-10-18	CI
Chong Kun Dang Holdings Corp.Ã†s Equity Buyback announced on October 15, 2020 has expired.	22-10-14	CI
Chong Kun Dang Holdings Corp.'s Equity Buyback announced on October 15, 2021, has expired with 75,857 shares, representing 1.54% for KRW 4,939.75 million.	22-10-13	CI
Chong Kun Dang Holdings Corp. announces an Equity Buyback for KRW 10,000 million worth of its shares.	22-08-12	CI
Chong Kun Dang Holdings Corp. authorizes a Buyback Plan.	22-08-11	CI
Bio Orchestra Co., Ltd. announced that it has received KRW 54 billion in funding from a group of investors	22-02-21	CI
Chong Kun Dang Holdings Corp. announces an Equity Buyback for KRW 10,000 million worth of its shares.	22-02-10	CI
Chong Kun Dang Holdings Corp. authorizes a Buyback Plan.	21-10-14	CI
Chong Kun Dang Holdings Corp. announces an Equity Buyback for KRW 5,000 million worth of its shares.	21-10-14	CI

Chart Chong Kun Dang Holdings Corp.

Duration

Period

More charts

Company Profile

CHONGKUNDANG HOLDINGS CORP., formerly Chong Kun Dang Pharmaceutical Corp., is a Korea-based company engaged in the investment business. Through its subsidiary, the Company provides pharmaceuticals, including remedies for high blood pressure and high cholesterol, immunosuppressive drugs, antitumor agents, antibiotics, remedies for erectile dysfunction and remedies for obesity. It also produces antitumor agents, antibiotics, digestives, circulation agents, respiratory agents, remedies for endocrine diseases, remedies for skin diseases, functional cosmetics and others, as well as pharmaceutical ingredients. On November 2, 2013, the Company divested its pharmaceutical business into a newly established wholly owned subsidiary. After the divestiture, the Company engages in the investment and holding business.

Sector

Food Processing

More about the company

Income Statement Evolution

More financial data

Ratings for Chong Kun Dang Holdings Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

60,700 KRW

Average target price

63,000 KRW

Spread / Average Target

+3.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
CHONG KUN DANG HOLDINGS CORP.	+2.53%	214M
ZHEJIANG NHU COMPANY LTD.	+16.86%	8.43B
BELLRING BRANDS, INC.	+3.57%	7.49B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+4.89%	6.23B
THE SIMPLY GOOD FOODS COMPANY	-5.23%	3.75B
BYHEALTH CO., LTD	-6.58%	3.75B
XIAMEN KINGDOMWAY GROUP COMPANY	-3.55%	1.33B
HERBALIFE LTD.	-28.64%	1.09B
SIRIO PHARMA CO., LTD.	+18.12%	1.02B
USANA HEALTH SCIENCES, INC.	-8.60%	933M

Special Foods & Wellbeing Products